GAMMA
Title: Gemcitabine and AMG 479 in metastatic pancreatic cancer
(GAMMA)
Full title: A phase 3, multicentre, randomized,
double-blind, placebo controlled, trial of AMG 479 or placebo in
combination with gemcitabine as first Line therapy for metastatic
adenocarcinoma of the pancreas
Phase III Trial
Why is this trial being carried out?
Gemcitabine is a chemotherapy drug that is often used to treat
pancreatic cancer. It is sometimes combined with other drugs to try
to improve treatment.
This trial is looking at whether combining gemcitabine with
another drug called AMG 479 is a more effective treatment for
metastatic pancreatic cancer than gemcitabine alone. It is also
looking at the side effects of this combined treatment.
AMG 479 is a human monoclonal antibody, a type of
treatment that stimulates the body's immune system. AMG 479 targets
the type 1 insulin-like growth factor receptor (IGF-1R), which is
involved in the regulation of cell growth and survival.
Who is the trial suitable for?
The trial is suitable for patients with pancreatic cancer that
has spread to another part of the body, and who have not have
previous chemotherapy or radiotherapy treatment for pancreatic
cancer. Your doctor(s) will explain these and any other
requirements to join the trial.
Trial centres
The trial is recruiting in Belfast, Birmingham, Hull, Leicester,
Manchester and Northampton.
Recruitment start date: April 2011
Recruitment end date: October 2013
For more information
Clinicaltrials.gov and UKCRN